EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   2.5.1.46 | Adenocarcinoma |
25261239 |
A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer. |
unassigned |
0 |
| 2.5.1.46 | Carcinogenesis |
31796630 |
Hypusine biosynthesis in ? cells links polyamine metabolism to facultative cellular proliferation to maintain glucose homeostasis. |
unassigned |
0 |
| 2.5.1.46 | Carcinoma |
15377278 |
Independent roles of eIF5A and polyamines in cell proliferation. |
ongoing research
therapeutic application
unassigned |
3
4
0 |
| 2.5.1.46 | Carcinoma |
27041563 |
The hypusine cascade promotes cancer progression and metastasis through the regulation of RhoA in squamous cell carcinoma. |
ongoing research
unassigned |
3
0 |
| 2.5.1.46 | Diabetes Mellitus, Type 1 |
23846959 |
Protective effects of polyamine depletion in mouse models of type 1 diabetes: implications for therapy. |
ongoing research
unassigned |
2
0 |
| 2.5.1.46 | Diabetes Mellitus, Type 1 |
24196968 |
Deoxyhypusine synthase promotes differentiation and proliferation of T helper type 1 (Th1) cells in autoimmune diabetes. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
2
3
3
2 |
| 2.5.1.46 | Diabetes Mellitus, Type 2 |
20956533 |
Inhibition of deoxyhypusine synthase enhances islet {beta} cell function and survival in the setting of endoplasmic reticulum stress and type 2 diabetes. |
causal interaction
ongoing research
therapeutic application
unassigned |
1
2
1
0 |
| 2.5.1.46 | Glioblastoma |
22927971 |
Expression of Eukaryotic Initiation Factor 5A and Hypusine Forming Enzymes in Glioblastoma Patient Samples: Implications for New Targeted Therapies. |
unassigned |
0 |
| 2.5.1.46 | Hyperglycemia |
23846959 |
Protective effects of polyamine depletion in mouse models of type 1 diabetes: implications for therapy. |
ongoing research
unassigned |
2
0 |
| 2.5.1.46 | Leishmaniasis |
25769972 |
Targeting polyamine metabolism for finding new drugs against leishmaniasis: a review. |
therapeutic application
unassigned |
1
0 |
